Investors

Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Net assets

£1340m

Fully diluted NAV per share

199.4p

Life science portfolio value

£517m

Capital pool supporting investment in life science

£823m

Portfolio snapshot

  • 13 portfolio companies in innovative areas of life science
  • 700+ employees across Syncona portfolio
  • 7 live clinical trials across the portfolio